Clinical Research Directory
Browse clinical research sites, groups, and studies.
COMPARISON OF INTRALESIONAL GLUCANTIME ALONE VERSUS COMBINED WITH FRACTIONAL CO2 LASER FOR ADULT CUTANEOUS LEISHMANIASIS
Sponsor: Combined military hospital Peshawar
Summary
Cutaneous leishmaniasis is a common parasitic skin disease causing chronic ulcerative lesions and scarring. Intralesional meglumine antimoniate (Glucantime) is a widely used treatment; however, healing may be prolonged and cosmetic outcomes may be suboptimal. Fractional CO₂ laser therapy may enhance drug penetration, accelerate healing, and improve cosmetic results. This randomized controlled trial aims to compare the healing outcomes of intralesional Glucantime alone versus intralesional Glucantime combined with fractional CO₂ laser therapy in adult patients with cutaneous leishmaniasis treated at CMH Peshawar. A total of 150 participants will be randomized in a 1:1 ratio and followed for assessment of clinical healing, lesion size reduction, cosmetic outcomes, and adverse events.
Official title: HEALING OUTCOMES OF INTRALESIONAL GLUCANTIME ALONE VERSUS GLUCANTIME COMBINED WITH FRACTIONAL CO₂ LASER IN ADULT CUTANEOUS LEISHMANIASIS
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
150
Start Date
2026-08-01
Completion Date
2027-06-30
Last Updated
2026-06-16
Healthy Volunteers
No
Conditions
Interventions
Meglumine Antimoniate
Intralesional meglumine antimoniate (Glucantime) administered according to the study protocol for treatment of cutaneous leishmaniasis.
Fractional CO₂ laser
Fractional carbon dioxide laser therapy administered according to the study protocol as an adjunct to intralesional meglumine antimoniate treatment for cutaneous leishmaniasis.
Locations (1)
Combined military hospital peshawar
Peshawar, Khyber Pukhtunkhwa, Pakistan